Armata Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $9 from $7 and keeps a Buy rating on the shares. The company this morning announced a “very big clinical win as well a defining moment for bacteriophage therapy,” the analyst tells investors in a research note. The firm says the Phase 1b/2a study, diSArm, has met all primary endpoints. The study and highlights, beyond the “strong” clinical responses, that from the petri dish to the patient, AP-SA02 shows the ability to home to site of infections, kill, amplify, and re-home to kill some more, before being cleared by the liver, contends H.C. Wainwright.